



## ONCOLOGY MEDICATION CLINICAL COVERAGE

Policy Number: [CSLA2019D0030Q](#)

Effective Date: [TBD](#)

[Instructions for Use](#)

### Table of Contents

	Page
<a href="#">APPLICATION</a>	1
<a href="#">COVERAGE RATIONALE</a>	1
<a href="#">APPLICABLE CODES</a>	3
<a href="#">BACKGROUND</a>	3
<a href="#">BENEFIT CONSIDERATIONS</a>	4
<a href="#">REFERENCES</a>	4
<a href="#">POLICY HISTORY/REVISION INFORMATION</a>	4
<a href="#">INSTRUCTIONS FOR USE</a>	5

### Related Community Plan Policy

- [Denosumab \(Prolia® & Xgeva®\)](#)
- [Erythropoiesis-Stimulating Agents](#)
- [Lemtrada \(Alemtuzumab\)](#)
- [Rituximab \(Rituxan®, Ruxience™, & Truxima®\)](#)
- [White Blood Cell Colony Stimulating Factors](#)

### Commercial Policy

- [Oncology Medication Clinical Coverage](#)

### Related Guidelines

- [Transplant Review Guidelines: Hematopoietic Stem Cell Transplantation](#)

### APPLICATION

This Medical Benefit Drug Policy only applies to the state of Louisiana.

### COVERAGE RATIONALE

See [Benefit Considerations](#)

#### Description

This policy provides parameters for coverage of injectable oncology medications [\(J9000–J9999\) and select ancillary and supportive care medications for oncology conditions](#) (including, but not limited to octreotide acetate [\(J2353 and J2354\)](#), leuprolide acetate [\(J1950\)](#), leucovorin [\(J0640\)](#) and levoleucovorin [\(J0641\)](#)), [including therapeutic radiopharmaceuticals](#), covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium® (NCCN Compendium®). The Compendium lists the appropriate drugs and biologics for specific cancers using U.S. Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. Each recommendation is supported by a level of evidence category. [Coverage of White Blood Cell Colony Stimulating Factors and Erythropoiesis-Stimulating Agents are addressed in separate policies](#). This policy does not provide coverage criteria for Chimeric Antigen Receptor (CAR)-T Cell products. Coverage determinations are based on the member's benefits and the OptumHealth Transplant Solutions criteria for covered transplants in the Clinical Guideline titled [Transplant Review Guidelines: Hematopoietic Stem Cell Transplantation](#).

### Coverage Rationale

The Oncology Products table below lists the UnitedHealthcare preferred oncology products and respective non-preferred products. Coverage will be provided for the UnitedHealthcare preferred oncology product contingent on the coverage criteria in the Diagnosis-Specific Criteria section.

Coverage for any respective non-preferred oncology product will be provided contingent on the criteria in the Medical Necessity Criteria and the Diagnosis-Specific Criteria sections.

### Medical Necessity Criteria

Treatment with the respective non-preferred product specified in the Oncology Products table below is medically necessary for oncology indications when BOTH of the following are met:

- History of intolerance or contraindication to the UnitedHealthcare preferred oncology product; and
- Physician attests that, in their clinical opinion, the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product

### Oncology Products

Below are UnitedHealthcare preferred oncology products with therapeutically equivalent and/or biosimilar\* non-preferred products as determined by the UnitedHealthcare P&T Committee:

Preferred Oncology Product	Non-Preferred Oncology Product
<u>Mvasi (bevacizumab-awwb)</u>	<u>Avastin (bevacizumab)</u> <u>Zirabev (bevacizumab-bvzr)</u>
<u>Kanjinti (trastuzumab-anns)</u>	<u>Herceptin</u> <u>Hylecta (trastuzumab and hyaluronidase-oysk)</u> <u>Herzuma (trastuzumab-pkrb)</u> <u>Ogviri (trastuzumab-dkst)</u> <u>Ontruzant (trastuzumab-dttb)</u> <u>Trazimera (trastuzumab-qvyp)</u>
<u>Gemcitabine</u> <u>Leucovorin</u>	<u>Infugem (gemcitabine in sodium chloride injection)</u> <u>Levoleucovorin</u>

\*Biosimilar means that the biological product is FDA-approved based on data demonstrating that it is highly similar to an already FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.

### Diagnosis-Specific Criteria

#### Injectable Oncology Medications

#### Injectable Oncology, Ancillary, and Supportive Care Medications

UnitedHealthcare recognizes indications and uses of injectable oncology medications, including therapeutic radiopharmaceuticals, listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as **proven and medically necessary**, and Categories of Evidence and Consensus of 3 as **unproven and not medically necessary**. (However, see [Benefit Considerations](#).)

UnitedHealthcare will cover all chemotherapy agents for individuals under the age of 19 years for oncology indications. The majority of pediatric patients receive treatments on national pediatric protocols that are quite similar in concept to the NCCN patient care guidelines.

Refer to Medical Necessity Criteria for the UnitedHealthcare preferred oncology products that have therapeutically equivalent and/or biosimilar products available.

Select ancillary and supportive care medications for oncology conditions have therapeutically equivalent products available. When a therapeutically equivalent alternative is available, as determined by the UnitedHealthcare Pharmacy and Therapeutics (P&T) Committee, certain medications may be excluded and/or not medically necessary. For purposes of the UnitedHealthcare P&T Committee review, therapeutic

**equivalence refers to medications that can be expected to produce essentially the same therapeutic outcome and adverse events.**

**Below are ancillary and supportive care medications for oncology conditions with therapeutically equivalent alternatives as determined by the UnitedHealthcare P&T Committee:**

- **Leucovorin (Preferred)**
- **Levoleucovorin (Non-Preferred)**

## **APPLICABLE CODES**

**The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.**

### **Coding Clarification:**

- **The denied drug codes apply to all outpatient places of service (including office, hospital, etc.).**

HCPCS Code	Description	Rationale
<u><b>Denied Drug Codes:</b></u>		
J9219	Leuprolide acetate implant, 65 mg	<u><b>Products Discontinued</b></u>

## **BACKGROUND**

### **Additional Information**

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are ~~a~~ comprehensive **set of 71** guidelines documenting **sequential** management decisions and interventions and interventions that apply to malignancies which apply to more than 97% of cancers affecting U.S. patients. ~~They also address supportive care issues. The guidelines are developed and updated by 54 volunteer panels, composed of more than 1,275 clinicians and oncology researchers representing the 27 NCCN member institutions and their affiliates.~~

### **NCCN Categories of Evidence and Consensus**

#### **Category 1**

The recommendation is based on high-level evidence (i.e., high-powered randomized clinical trials or meta-analyses), and the panel has reached uniform consensus that the recommendation is indicated. In this context, uniform means near unanimous positive support with some possible neutral positions.

#### **Category 2A**

The recommendation is based on lower level evidence, but despite the absence of higher level studies, there is uniform consensus that the recommendation is appropriate. Lower level evidence is interpreted broadly, and runs the gamut from phase II to large cohort studies to case series to individual practitioner experience. Importantly, in many instances, the retrospective studies are derived from clinical experience of treating large numbers of patients at a member institution, so panel members have first-hand knowledge of the data. Inevitably, some recommendations must address clinical situations for which limited or no data exist. In these instances the congruence of experience-based opinions provides an informed if not confirmed direction for optimizing patient care. These recommendations carry the implicit recognition that they may be superseded as higher level evidence becomes available or as outcomes-based information becomes more prevalent.

#### **Category 2B**

The recommendation is based on lower level evidence, and there is nonuniform consensus that the recommendation should be made. In these instances, because the evidence is not conclusive, institutions take different approaches to the management of a particular clinical scenario. This nonuniform consensus does not represent a major disagreement.

rather it recognizes that given imperfect information, institutions may adopt different approaches. A Category 2B designation should signal to the user that more than one approach can be inferred from the existing data.

### Category 3

The recommendation has engendered a major disagreement among the panel members. Several circumstances can cause major disagreements. For example, if substantial data exist about two interventions but they have never been directly compared in a randomized trial, adherents to one set of data may not accept the interpretation of the other side's results. Another situation resulting in a Category 3 designation is when experts disagree about how trial data can be generalized. A Category 3 designation alerts users to a major interpretation issue in the data and directs them to the manuscript for an explanation of the controversy.

**Therapeutic radiopharmaceuticals (e.g., Azedra® (iodobenguane I-131), Lutathera® (lutetium Lu 177 dotatate), Xofigo® (radium-223)) used to treat cancer are medications that contain radioactive material. The radioactive agent selectively accumulates within the tumor releasing radiation which then kills cancer cells.**

## BENEFIT CONSIDERATIONS

Chimeric Antigen Receptor (CAR)-T Cell Therapy may be eligible for coverage as an autologous stem cell therapy under a member's Transplantation Services benefit. Coverage determinations are based on the OptumHealth Transplant Solutions criteria for covered transplants in the Clinical Guideline titled [Transplant Review Guidelines: Hematopoietic Stem Cell Transplantation](#).

## REFERENCES

1. The NCCN Drugs and Biologics Compendium (NCCN Compendium®).  
[http://www.nccn.org/professionals/drug\\_compendium/content/contents.asp](http://www.nccn.org/professionals/drug_compendium/content/contents.asp).
2. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).  
[http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).
3. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13 Suppl 2:19-21.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.
- 4.5. **Center for Drug Evaluation and Research. Biosimilars. Retrieved from: <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars>.**

## POLICY HISTORY/REVISION INFORMATION

Date	Action/Description
	<p><u><b>Template Update</b></u></p> <ul style="list-style-type: none"><li>• <u><b>Reorganized policy template:</b></u><ul style="list-style-type: none"><li>◦ <u><b>Simplified and relocated <i>Application</i> section; previously titled <i>State Exceptions</i></b></u></li></ul></li><li>• <u><b>Added reference link to the related Medical Benefit Drug Policy titled <i>Erythropoiesis-Stimulating Agents</i></b></u></li><li>• <u><b>Added the <i>Background</i> section header</b></u></li><li>• <u><b>Added the <i>Applicable Codes</i> section</b></u><ul style="list-style-type: none"><li>◦ <u><b>Included J9219 due to product discontinuation 01/03/2008.</b></u></li></ul></li></ul>
	<p><u><b>Coverage Rationale</b></u></p> <ul style="list-style-type: none"><li>• <u><b>Removed specific HCPCS codes and language pertaining to "select ancillary and supportive care medications for oncology conditions"</b></u></li><li>• <u><b>Added language to indicate:</b></u><ul style="list-style-type: none"><li>◦ <u><b>The policy guidelines apply to therapeutic radiopharmaceuticals</b></u></li><li>◦ <u><b>Coverage of White Blood Cell Colony Stimulating Factors and</b></u></li></ul></li></ul>

**Proprietary Information of United Healthcare:** The information contained in this document is proprietary and the sole property of United HealthCare Services, Inc. Unauthorized copying, use and distribution of this information are strictly prohibited. Copyright 2020 United HealthCare Services, Inc.

Date	Action/Description
	<p><u><i>Erythropoiesis-Stimulating Agents is addressed in a separate policy</i></u></p> <ul style="list-style-type: none"> <li>○ <u><i>The Oncology Products table lists the UnitedHealthcare preferred oncology products and respective non-preferred products; coverage will be provided for the UnitedHealthcare preferred oncology product contingent on the coverage criteria in the <i>Diagnosis-Specific Criteria</i> section of the policy</i></u></li> <li>○ <u><i>Coverage for any respective non-preferred oncology product will be provided contingent on the criteria in the <i>Medical Necessity Criteria</i> and the <i>Diagnosis-Specific Criteria</i> sections of the policy</i></u></li> <li>▪ <u><i>Treatment with the respective non-preferred product specified in the Oncology Products table is medically necessary for oncology indications when both of the following are met:</i></u> <ul style="list-style-type: none"> <li>- <u><i>History of intolerance or contraindication to the UnitedHealthcare preferred oncology product; and</i></u></li> <li>- <u><i>Physician attests that, in their clinical opinion, the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product</i></u></li> </ul> </li> <li>○ <u><i>The Oncology Products table lists the UnitedHealthcare preferred oncology products with therapeutically equivalent and/or biosimilar non-preferred products as determined by the UnitedHealthcare Pharmacy and Therapeutics (P&amp;T) Committee; biosimilar means that the biological product is FDA-approved based on data demonstrating that it is highly similar to an already FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product</i></u></li> </ul> <p><u><i>Diagnosis-Specific Criteria</i></u></p> <ul style="list-style-type: none"> <li>○ <u><i>Refer to the <i>Medical Necessity Criteria</i> section of the policy for the UnitedHealthcare preferred oncology products that have therapeutically equivalent and/or biosimilar products available</i></u></li> </ul> <p><u><i>Background</i></u></p> <ul style="list-style-type: none"> <li>○ <u><i>Deleted <i>Additional Information</i> header</i></u></li> <li>○ <u><i>Modified language to indicate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprehensive guidelines documenting management decisions and interventions and interventions that apply to malignancies which apply to more than 97% of cancers affecting U.S. patients</i></u></li> <li>○ <u><i>Added language pertaining to Therapeutic Radiopharmaceuticals</i></u></li> </ul> <p><u><i>Supporting Information</i></u></p> <p><u><i>Updated <i>References</i> section to reflect the most current information</i></u></p>

## INSTRUCTIONS FOR USE

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.